Allovir IncNASDAQ:ALVRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7855
- TODAY'S CHANGE (%)-0.0328 (-4.0083%)
- Bid / Lots0.7800/ 24
- Ask / Lots0.8200/ 1
- Open / Previous Close0.8100 / 0.8183
- Day Range
- 52 Week Range
- Volume114,690
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVR |
|---|---|---|
| 09:32 ET | 100 | 0.81 |
| 09:50 ET | 114 | 0.8148 |
| 09:54 ET | 1000 | 0.8124 |
| 09:57 ET | 503 | 0.8013 |
| 10:19 ET | 100 | 0.808 |
| 10:24 ET | 4227 | 0.8053 |
| 10:26 ET | 100 | 0.8097 |
| 10:30 ET | 14435 | 0.808 |
| 10:32 ET | 616 | 0.815 |
| 10:33 ET | 217 | 0.815 |
| 10:35 ET | 200 | 0.815 |
| 10:42 ET | 100 | 0.8055 |
| 10:53 ET | 100 | 0.8055 |
| 11:02 ET | 150 | 0.81 |
| 11:08 ET | 100 | 0.8055 |
| 11:15 ET | 1938 | 0.81 |
| 11:20 ET | 246 | 0.81 |
| 11:27 ET | 3730 | 0.802993 |
| 11:29 ET | 200 | 0.8055 |
| 11:33 ET | 200 | 0.8055 |
| 11:40 ET | 200 | 0.8055 |
| 11:44 ET | 7523 | 0.78565 |
| 11:45 ET | 200 | 0.7867 |
| 11:47 ET | 300 | 0.780801 |
| 11:49 ET | 200 | 0.7866 |
| 11:51 ET | 200 | 0.7808 |
| 11:54 ET | 400 | 0.7801 |
| 11:56 ET | 400 | 0.7808 |
| 12:05 ET | 200 | 0.7808 |
| 12:07 ET | 18100 | 0.78 |
| 12:09 ET | 1350 | 0.7853 |
| 12:18 ET | 200 | 0.7849 |
| 12:38 ET | 16561 | 0.790499 |
| 12:39 ET | 5100 | 0.7855 |
| 12:41 ET | 5000 | 0.7905 |
| 12:45 ET | 1500 | 0.7853 |
| 12:50 ET | 100 | 0.78 |
| 12:54 ET | 100 | 0.7855 |
| 01:01 ET | 3100 | 0.78 |
| 01:10 ET | 5000 | 0.790499 |
| 01:12 ET | 100 | 0.78 |
| 01:14 ET | 100 | 0.7853 |
| 01:19 ET | 500 | 0.7906 |
| 01:26 ET | 108 | 0.7906 |
| 01:30 ET | 100 | 0.7855 |
| 01:33 ET | 100 | 0.78 |
| 01:35 ET | 185 | 0.78 |
| 01:44 ET | 100 | 0.781 |
| 01:48 ET | 200 | 0.7853 |
| 01:53 ET | 100 | 0.781 |
| 02:02 ET | 100 | 0.781 |
| 02:11 ET | 100 | 0.781 |
| 02:13 ET | 100 | 0.7806 |
| 02:20 ET | 100 | 0.7905 |
| 02:29 ET | 200 | 0.78 |
| 02:36 ET | 100 | 0.7905 |
| 02:38 ET | 100 | 0.78 |
| 02:44 ET | 850 | 0.78525 |
| 02:45 ET | 100 | 0.781 |
| 02:47 ET | 100 | 0.7801 |
| 02:51 ET | 100 | 0.7905 |
| 02:56 ET | 100 | 0.78 |
| 02:58 ET | 200 | 0.7801 |
| 03:02 ET | 200 | 0.78525 |
| 03:03 ET | 100 | 0.781 |
| 03:07 ET | 100 | 0.7905 |
| 03:09 ET | 100 | 0.7905 |
| 03:12 ET | 200 | 0.7905 |
| 03:16 ET | 100 | 0.7853 |
| 03:18 ET | 200 | 0.781 |
| 03:21 ET | 100 | 0.7855 |
| 03:23 ET | 2700 | 0.78525 |
| 03:25 ET | 200 | 0.78525 |
| 03:34 ET | 100 | 0.7905 |
| 03:36 ET | 200 | 0.78 |
| 03:41 ET | 200 | 0.78 |
| 03:45 ET | 200 | 0.7905 |
| 03:50 ET | 300 | 0.7905 |
| 03:52 ET | 400 | 0.7905 |
| 03:54 ET | 300 | 0.7905 |
| 03:56 ET | 200 | 0.7905 |
| 03:57 ET | 200 | 0.7905 |
| 03:59 ET | 1149 | 0.7855 |
Sep 16, 2024
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm, from 11:16AM ET on Monday Sep 16, 2024 by Dow Jones
11:16AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allovir Inc | 90.6M | -0.6x | --- |
Genenta Science SPA | 80.2M | -6.3x | --- |
ALX Oncology Holdings Inc | 88.5M | -0.5x | --- |
Hillevax Inc | 88.1M | -0.5x | --- |
Genelux Corp | 87.0M | -2.6x | --- |
Citius Oncology Inc | 84.9M | 4.9x | --- |
Company Information
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Contact Information
- Headquarters
- 1100 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 617-433-2605
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- David Hallal
- President, Chief Financial Officer, Director
- Vikas Sinha
- Chief Executive Officer, Director
- Diana Brainard
- Co-Founder, Chief Scientific Officer
- Ann Leen
- Chief Accounting Officer
- Brett Hagen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $90.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 115.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-1.23 |
Book Value | $1.28 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
